Bank of America Securities has become more cautious on Crescent Capital, a business development company (BDC), downgrading the stock to neutral from a more positive rating and trimming its price target to $10.25. The move comes as the bank points to lingering credit problems in Crescent's legacy loan portfolio, which continue to weigh on the company's earnings power.
What's behind the cautious stance?
The core of the issue is Crescent's legacy FCRD loan book. According to BofA, this portfolio represents about 8% of Crescent's total investments at cost, but it accounts for roughly 27% of the company's nonaccruals. Nonaccruals are loans that have stopped paying interest, often because the borrower is in financial distress. When a loan goes on nonaccrual, the lender no longer recognizes interest income from it, which directly hits the bottom line.
For a BDC like Crescent, which is required to distribute most of its taxable income to shareholders, a drop in interest income can translate into lower dividends. More importantly, if those nonaccruing loans eventually default, the expected losses can reduce the value of the company's assets, pulling down its net asset value (NAV) per share. NAV is a key metric for BDCs because it represents the underlying value of the loan portfolio and is closely watched by investors.
Why this matters for investors
BDCs are popular among income-focused investors because they typically pay high dividends. But those dividends are only sustainable if the underlying loans perform. When a meaningful chunk of the portfolio is not generating interest, it raises questions about future payouts and the overall health of the investment.
BofA's downgrade is a signal that the bank sees these credit issues as more than a temporary blip. The new price target of $10.25 suggests the stock may have limited upside from current levels, at least in the near term. For everyday investors, this is a reminder that high yields often come with higher risk, especially when a company's loan book shows signs of stress.
Context: BDCs and credit cycles
Business development companies are investment vehicles that lend to small and mid-sized businesses, often taking on more risk than traditional banks. They are regulated and must meet certain requirements, but they are still exposed to the credit cycle. When the economy slows or interest rates rise, borrowers may struggle to make payments, leading to more nonaccruals and potential losses.
Crescent's situation is not unique. Many BDCs that grew rapidly during the last cycle are now dealing with legacy portfolios that are underperforming. The key for investors is to monitor how much of a BDC's portfolio is on nonaccrual and whether the company is setting aside enough reserves to cover potential losses.
What to watch next
Investors will be watching Crescent's upcoming earnings reports for any signs of improvement or further deterioration in the FCRD book. Management's commentary on credit quality and their plans for the legacy portfolio will be crucial. Also, any changes to the dividend could be a major catalyst, either positive or negative.
In the broader market, BDCs have been under pressure as interest rates have stayed higher for longer, increasing borrowing costs for their portfolio companies. The widening US-China bond yield gap has also been pulling capital toward US assets, which could affect funding conditions for smaller lenders. Meanwhile, rising oil prices have stoked inflation fears, which could keep central banks cautious about cutting rates, prolonging the pressure on BDCs.
Bottom line
BofA's downgrade is a caution flag for Crescent Capital investors. The legacy FCRD portfolio remains a drag, and the elevated nonaccrual rate suggests that credit issues are not fully resolved. For those holding the stock, it's worth keeping a close eye on the company's credit metrics and dividend sustainability. As always, diversification and a clear understanding of the risks are key when investing in high-yield vehicles like BDCs.
